News

Under the terms of the agreement, Gene Bridges has licensed the Red/ET technology to Novozymes for the purpose of genetically engineering recombinant micro-organisms for use in industrial applications.

Bennu’s Phase IIa clinical study is being conducted in Hawaii. The study is examining an oral administration of the current liquid injectable dose form of 4-methylpyrazole (4-MP) that

Both studies were performed in a murine model in which the low-density lipoprotein (LDL) receptor, which is responsible for the maintenance of normal serum cholesterol levels, has been

The agreement was extended an additional three years and is valued in the mid-six figures. This pharmaceutical company is said to be yet another customer that has demonstrated

The study was a, multi-national, open-label trial of 160 patients who were receiving oral lacosamide for at least eight weeks. For the last two weeks of the trial,

Obetech’s partnership with Scandinavian Clinical Nutrition (SCN) will result in the formation of a new Swedish company, Scandivir, which will be co-owned by both organizations. Through this partnership,

The agreement is for an initial term of seven years and automatically renews for successive four year terms unless a written notice of intent to terminate is provided

The open-label study will enroll approximately 40 patients with advanced non-small cell lung cancer, pancreatic cancer or melanoma for whom standard approved therapy is not available. The study

In this study, 45 patients with locally advanced ErbB2 over-expressing breast cancer, received lapatinib before surgery, initially as a single agent for the first six weeks, followed by